Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors
Year: 2016
Type: article
Source: Annals of Oncology
Authors: E. Geretti, C. Espelin, B. Adiwijaya, N. Dumont, S. Coma, Z. Koncki, G. Garcia, T. Bloom, V. Rimkunas, J. Reynolds, K. Campbell, V. Moyo, I. Molnar, P. Lorusso, K. Miller, C. Ma, I.E. Krop, P. Munster, T. Wickham
Institutions: Merrimack Pharmaceuticals (United States), Yale Cancer Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Washington University in St. Louis, Dana-Farber Cancer Institute, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2589089516